TOP > 外国特許検索 > PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYDROCEPHALUS

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYDROCEPHALUS NEW

外国特許コード F180009458
整理番号 (S2017-0064-N0)
掲載日 2018年7月31日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP038203
国際公開番号 WO 2018079493
国際出願日 平成29年10月23日(2017.10.23)
国際公開日 平成30年5月3日(2018.5.3)
優先権データ
  • 特願2016-208438 (2016.10.25) JP
発明の名称 (英語) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYDROCEPHALUS NEW
発明の概要(英語) The purpose of the present invention is to provide a new pharmaceutical composition for prevention or treatment of hydrocephalus, and a diagnosis kit that does not place a heavy burden on a patient. Further, the purpose of the present invention is to provide a new method for prevention and treatment of hydrocephalus as well as a diagnosis method of hydrocephalus that reduces the burden on a patient. Provided are: a pharmaceutical composition for prevention or treatment of hydrocephalus, the composition containing a Tsukushi protein; a method for diagnosing hydrocephalus that includes the detection of amino acid substitution of a Tsukushi protein or a Tsukushi gene mutation which causes such amino acid substitution; and the like.
特許請求の範囲(英語) [claim1]
1. Comprising a protein Tsukushi, hydrocephalus for prevention or treatment of a pharmaceutical composition.
[claim2]
2. Wherein the protein Tsukushi, produced by a genetic engineering technique Tsukushi protein, a pharmaceutical composition according to claim 1.
[claim3]
3. Wherein the protein Tsukushi, (a) an amino acid sequence shown in SEQ ID NO:1 protein, or (b) in the amino acid sequence shown in SEQ ID NO:1, one or more amino acids 1 and/or substituted and/or deletion insertion and/or addition of an amino acid sequence, and the prevention or treatment of hydrocephalus protein having an activity, however, a cysteine substitution at position 208 of arginine ACPPE, in which the pharmaceutical composition according to claim 1 or 2.
[claim4]
4. Wherein the protein Tsukushi, hydrocephalus suffering from a brain of a mammal administered directly or indirectly to the chamber so that the formulation as claimed in any one of claims 1-3 pharmaceutical composition.
[claim5]
5. Any one of claims 1-4 pharmaceutical composition to a mammal comprising administering an effective amount, in a mammal in need of preventing or treating hydrocephalus.
[claim6]
6. The detection of mutations of the protein by Tsukushi, mammalian subject is suffering from hydrocephalus or predisposition to a subject suffering from a method of determining in a biological sample from the subject, (1) a mammal, R208C, S248N and V308I is selected from the group consisting of substituted and unsubstituted forms Tsukushi Tsukushi substituted and unsubstituted forms the protein or protein-encoding nucleic acid comprises the step of detecting, (2) substituted and unsubstituted forms step (1) Tsukushi substituted Tsukushi protein or a nucleic acid encoding a protein is in the presence of the case, the mammal is a human subject is suffering from hydrocephalus or predisposition to a subject suffering from the step of determining, including, method.
[claim7]
7. Claim R208C mutations in the protein Tsukushi, method according to claim 6.
[claim8]
8. Wherein the mammal is a human subject, method according to claim 6 or 7.
[claim9]
9. Wherein the variation of the protein Tsukushi, RNA or DNA in the biological sample and detecting the method of any one of claims 6-8.
[claim10]
10. In which the living sample is a blood or cerebral spinal fluid, the method of any one of claims 6-9.
[claim11]
11. The biological sample is blood, method according to claim 10.
[claim12]
12. R208C, S248N And V308I are selected from the group consisting of the amino acid substitutions Tsukushi Tsukushi mutations in the gene nucleic acids that can be detected.
[claim13]
13. Wherein the nucleic acid, 1) by a base sequence of SEQ ID NO:2 622 of the third base mutation in a thymine cytosin (uracil), 2) by a base sequence of a sequence of 2 743 in the third base mutation to adenine guanie, and 3) the nucleotide sequence represented by sequence number 2 of the second and third bases adenine guanie in 922 to 1 at least one selected from the group consisting of mutation of the nucleotide sequence containing the one or mutation site, a sequence of the nucleotide sequence represented by 5-100 2 from the base portion of the sequence or a subsequence thereof of any one of the complementary sequence or is capable of hybridizing under stringent conditions with a nucleotide sequence according to claim 12 made from a marker or a nucleic acid.
[claim14]
14. Comprising a nucleic acid according to claim 12 or 13, hydrocephalus diagnostic kit.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • OHTA KUNIMASA
  • ITO NAOFUMI
  • AHMAD SHAH ADIL ISHTIYAQ
国際特許分類(IPC)
指定国 (WO201879493)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close